"ファイザー" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonPfizer: Tanya Alcorn Moves to Lead Hospitals & Biosimilars - Healthcare Digital
Pfizer: Tanya Alcorn Moves to Lead Hospitals & Biosimilars Healthcare Digital
I’m the former head of Pfizer R&D. I’m very worried about biopharma’s future - statnews.com
I’m the former head of Pfizer R&D. I’m very worried about biopharma’s future statnews.com
Better Buy in 2026: Pfizer or Merck? - The Motley Fool
Better Buy in 2026: Pfizer or Merck? The Motley Fool
Pfizer RNA leader runs to Replicate—Chutes & Ladders - Fierce Biotech
Pfizer RNA leader runs to Replicate—Chutes & Ladders Fierce Biotech
Looking Beyond Novo Nordisk, High-Yield Pfizer Is a Bigger Contrarian Opportunity - NAI500
Looking Beyond Novo Nordisk, High-Yield Pfizer Is a Bigger Contrarian Opportunity NAI500
Pfizer (PFE) CEO’s Struggling Because Of “a Good Hand,” Says Jim Cramer - Yahoo Finance
Pfizer (PFE) CEO’s Struggling Because Of “a Good Hand,” Says Jim Cramer Yahoo Finance
Accelerating Innovation: Pfizer’s 2025 AI Festival - Pfizer
Pfizer stock surge depends on risky $10B obesity gamble - Rolling Out
Pfizer stock surge depends on risky $10B obesity gamble Rolling Out
Pfizer: Downgrade To 'Hold' On Lower 2026 Revenue Guidance And Potential Growth Tracks - Seeking ...
Pfizer: Downgrade To 'Hold' On Lower 2026 Revenue Guidance And Potential Growth Tracks Seeking Alpha
Pfizer’s modest 2026 outlook shows its big investments will take time to pay off - CNBC
Pfizer’s modest 2026 outlook shows its big investments will take time to pay off CNBC
Pfizer CEO Defends Vaccines, Promises Growth by End of Decade - Barron's
Pfizer CEO Defends Vaccines, Promises Growth by End of Decade Barron's
Former Pfizer R&D chief not so ‘optimistic’ about biopharma now - statnews.com
Former Pfizer R&D chief not so ‘optimistic’ about biopharma now statnews.com
Is Pfizer A Recovery Opportunity After Covid Vaccine Boom Fades? - Yahoo Finance
Is Pfizer A Recovery Opportunity After Covid Vaccine Boom Fades? Yahoo Finance
Better Buy in 2026: Pfizer or Eli Lilly? - The Motley Fool
Better Buy in 2026: Pfizer or Eli Lilly? The Motley Fool
Athira inks Sermonix deal to power ex-Pfizer asset toward phase 3 breast cancer data - Fierce Bio...
Athira inks Sermonix deal to power ex-Pfizer asset toward phase 3 breast cancer data Fierce Biotech
Pfizer Isn’t Dead Money, Pipeline Execution Can Spark A Rebound (NYSE:PFE) - Seeking Alpha
Pfizer Isn’t Dead Money, Pipeline Execution Can Spark A Rebound (NYSE:PFE) Seeking Alpha
A much-needed win for Pfizer - statnews.com
A much-needed win for Pfizer statnews.com
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock - Yahoo Finance
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock Yahoo Finance
Novo files for CagriSema approval; Merck and Pfizer’s trial win - Yahoo Finance
Novo files for CagriSema approval; Merck and Pfizer’s trial win Yahoo Finance
Better Buy in 2026: Pfizer or Eli Lilly? - Yahoo Finance
Better Buy in 2026: Pfizer or Eli Lilly? Yahoo Finance
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock - Zacks Investment Research
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock Zacks Investment Research
Pfizer Stock Can Sink More. Here Is How - Forbes
Pfizer faces challenging years on fading COVID sales, margin pressure - Reuters
Pfizer faces challenging years on fading COVID sales, margin pressure Reuters
Pfizer shares drop 5% with 2026 revenue projection and long-range outlook - Fierce Pharma
Pfizer shares drop 5% with 2026 revenue projection and long-range outlook Fierce Pharma
Pfizer shares slide on pessimistic projections - The Pharma Letter
Pfizer shares slide on pessimistic projections The Pharma Letter
Pfizer (PFE) Valuation Check as Padcev–Keytruda Success and Obesity Deals Recast Its Post‑COVID G...
Pfizer (PFE) Valuation Check as Padcev–Keytruda Success and Obesity Deals Recast Its Post‑COVID Growth Story simplywall.st
Pfizer’s Stock Reacts to Decreases in 2026 Revenue Projections in Full-Year 2026 Guidance Release...
Pfizer’s Stock Reacts to Decreases in 2026 Revenue Projections in Full-Year 2026 Guidance Release PharmExec.com
Pfizer faces challenging years on fading COVID sales, margin pressure - The Spokesman-Review
Pfizer faces challenging years on fading COVID sales, margin pressure The Spokesman-Review
Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors C...
Pfizer, GSK & CVS Health: This Week's Top Healthcare Stories - Healthcare Digital
Pfizer, GSK & CVS Health: This Week's Top Healthcare Stories Healthcare Digital
Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update (NYSE:PFE) - Seeking ...
Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update (NYSE:PFE) Seeking Alpha
Pfizer: Ignoring The Dead Cat Bounce (NYSE:PFE) - Seeking Alpha
Pfizer: Ignoring The Dead Cat Bounce (NYSE:PFE) Seeking Alpha
Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise; Here's Why - Investor's Business Daily
Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise; Here's Why Investor's Business Daily
Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update (NYSE:PFE) - Seeking ...
Pfizer: 2026 Feels Like Another Lost Year After Yesterday's Guidance Update (NYSE:PFE) Seeking Alpha
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research - Reuters
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research Reuters
Why Pfizer (PFE) Stock Is Sliding Today - Yahoo Finance
Why Pfizer (PFE) Stock Is Sliding Today Yahoo Finance
Tepid 2026 outlook dents Pfizer shares - Yahoo Finance
Tepid 2026 outlook dents Pfizer shares Yahoo Finance
Animals Used in Research - Pfizer
Animals Used in Research Pfizer
Pfizer Forecasts Flat 2026 Sales as It Builds Drug Pipeline - Bloomberg.com
Pfizer Forecasts Flat 2026 Sales as It Builds Drug Pipeline Bloomberg.com
First Bank & Trust Buys 80,401 Shares of Pfizer Inc. $PFE - MarketBeat
First Bank & Trust Buys 80,401 Shares of Pfizer Inc. $PFE MarketBeat
Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts - Fierce Biotech
Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts Fierce Biotech
Pfizer foresees challenging 2026 on fading COVID sales, margin pressure - Denver Gazette
Pfizer foresees challenging 2026 on fading COVID sales, margin pressure Denver Gazette
Pfizer Issue Warning Over Birth Control Shot After Link to Brain Tumors - Newsweek
Pfizer Issue Warning Over Birth Control Shot After Link to Brain Tumors Newsweek
Morgan Doctoral Student Selected as Pfizer Fellow Advancing Vaccine Innovation - Morgan State Uni...
Morgan Doctoral Student Selected as Pfizer Fellow Advancing Vaccine Innovation Morgan State University
Novo obesity partner nabs Pfizer vet as CBO; CureVac's leadership clears out as BioNTech takes ov...
Novo obesity partner nabs Pfizer vet as CBO; CureVac's leadership clears out as BioNTech takes over Endpoints News
Pfizer Inc (PFE) Rating Steady Amid Neutral Market Outlook and Pipeline Progress - Yahoo Finance
Pfizer Inc (PFE) Rating Steady Amid Neutral Market Outlook and Pipeline Progress Yahoo Finance
Pfizer Sees 2026 Profit Below Estimates as COVID Sales Decline - Yahoo Finance
Pfizer Sees 2026 Profit Below Estimates as COVID Sales Decline Yahoo Finance
Inside Pfizer’s Report on Climate Change Linked Healthcare - Healthcare Digital
Inside Pfizer’s Report on Climate Change Linked Healthcare Healthcare Digital
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline C...
Pfizer’s stock drops after drug giant lowers its revenue forecast - MarketWatch
Pfizer’s stock drops after drug giant lowers its revenue forecast MarketWatch
Pfizer’s birth control injection has a new safety label, reflecting potential brain tumors - Medi...
Pfizer’s birth control injection has a new safety label, reflecting potential brain tumors Medical Marketing and Media
Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst F...
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance - Business Wire
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance Business Wire
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda - S...
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda Seeking Alpha
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharma...
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. The Motley Fool
Pfizer trims 2026 profit forecast amid Covid headwinds and patent cliff pressures - Pharmaceutica...
Pfizer trims 2026 profit forecast amid Covid headwinds and patent cliff pressures Pharmaceutical Technology
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025 - Pfizer
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025 Pfizer
Pfizer and Metsera Collaboration Highlights Biopharma Developments Amid Vaccine Regulatory Challe...
Pfizer and Metsera Collaboration Highlights Biopharma Developments Amid Vaccine Regulatory Challenges geneonline.com
Health Answers by Pfizer Launches Spanish-Language Expansion - Pfizer
Health Answers by Pfizer Launches Spanish-Language Expansion Pfizer
Pfizer-Cipla Seal India Marketing Deal: What It Entails - Citeline News & Insights
Pfizer-Cipla Seal India Marketing Deal: What It Entails Citeline News & Insights
Pfizer Adds to Its Big Bet on Weight Loss Drugs - Yahoo Finance
Pfizer Adds to Its Big Bet on Weight Loss Drugs Yahoo Finance
Pfizer Racks Up Awards for Podcast, More - Pfizer
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future? - Nasdaq
Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future? Nasdaq
Adams Asset Advisors LLC Boosts Stock Position in Pfizer Inc. $PFE - MarketBeat
Adams Asset Advisors LLC Boosts Stock Position in Pfizer Inc. $PFE MarketBeat
Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast - The Motley Fool
Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast The Motley Fool
FDA approves brain tumor warning on Depo-Provera label as court battle grows over side effects - ...
FDA approves brain tumor warning on Depo-Provera label as court battle grows over side effects statnews.com
Federal lawsuit accuses Teva of colluding with Pfizer to delay releasing generic drugs - The Busi...
Federal lawsuit accuses Teva of colluding with Pfizer to delay releasing generic drugs The Business Journals
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Cat...
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note Yahoo Finance
Bernstein reiterates Pfizer stock rating, sees constrained recovery path - Investing.com
Bernstein reiterates Pfizer stock rating, sees constrained recovery path Investing.com
Pfizer lets anyone listen in as it reviews its 2025 performance results - Stock Titan
Pfizer lets anyone listen in as it reviews its 2025 performance results Stock Titan
Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings - The Wall Street Journal
Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings The Wall Street Journal
Wilsey Asset Management Inc. Purchases 118,248 Shares of Pfizer Inc. $PFE - MarketBeat
Wilsey Asset Management Inc. Purchases 118,248 Shares of Pfizer Inc. $PFE MarketBeat
Facing multibillion-dollar patent cliff, Pfizer plans slew of obesity trials - Endpoints News
Facing multibillion-dollar patent cliff, Pfizer plans slew of obesity trials Endpoints News
Wedge Capital Management L L P NC Has $26.91 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Wedge Capital Management L L P NC Has $26.91 Million Stock Position in Pfizer Inc. $PFE MarketBeat
Pfizer CEO Says US Vaccine Policy Changes A Political ‘Anomaly’ - Citeline News & Insights
Pfizer CEO Says US Vaccine Policy Changes A Political ‘Anomaly’ Citeline News & Insights
Pfizer Inc. (NYSE:PFE) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Pfizer Inc. (NYSE:PFE) Receives Average Recommendation of "Hold" from Analysts MarketBeat
Foster Victor Wealth Advisors LLC Purchases 60,667 Shares of Pfizer Inc. $PFE - MarketBeat
Foster Victor Wealth Advisors LLC Purchases 60,667 Shares of Pfizer Inc. $PFE MarketBeat
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts t...
Addenda Capital Inc. Boosts Stock Position in Pfizer Inc. $PFE - MarketBeat
Addenda Capital Inc. Boosts Stock Position in Pfizer Inc. $PFE MarketBeat
Pfizer stock price target lowered to $24 at Wolfe Research on underperformance - Investing.com
Pfizer stock price target lowered to $24 at Wolfe Research on underperformance Investing.com
Pfizer leads COVID-19 vaccine peers lower after revamped guidance - Seeking Alpha
Pfizer leads COVID-19 vaccine peers lower after revamped guidance Seeking Alpha
President announces TrumpRx website for drugs, and pricing deal with Pfizer - NPR
President announces TrumpRx website for drugs, and pricing deal with Pfizer NPR
Pfizer sees flat 2026 sales as it rebuilds drug pipeline - Crain's New York Business
Pfizer sees flat 2026 sales as it rebuilds drug pipeline Crain's New York Business
2 Headwinds Facing Pfizer Stock Going Into 2026 - The Motley Fool
2 Headwinds Facing Pfizer Stock Going Into 2026 The Motley Fool
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung C...
Pfizer Stock (PFE) on Dec. 18, 2025: Latest News, 2026 Forecast, Analyst Price Targets, Dividend,...
Pfizer tops estimates, raises profit guidance even as sales fall - CNBC
Pfizer tops estimates, raises profit guidance even as sales fall CNBC
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance - BioSpace
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance BioSpace
Pfizer Stands By Vaccines Investment Despite Political ‘Anomaly’ - Citeline News & Insights
Pfizer Stands By Vaccines Investment Despite Political ‘Anomaly’ Citeline News & Insights
Stocks making the biggest moves premarket: Pfizer, Roku, Kraft Heinz & more - CNBC
Stocks making the biggest moves premarket: Pfizer, Roku, Kraft Heinz & more CNBC
Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wal...
Pfizer Stock Fell 3.4% Yesterday On Modest 2026 Outlook - TIKR.com
Pfizer Stock Fell 3.4% Yesterday On Modest 2026 Outlook TIKR.com
Pfizer Launches “Power of Knowing” Video Series with Chief Digital and Technology Officer - Pfizer
Pfizer Launches “Power of Knowing” Video Series with Chief Digital and Technology Officer Pfizer
Guggenheim maintains Buy rating on Pfizer stock, sets $35 price target - Investing.com
Guggenheim maintains Buy rating on Pfizer stock, sets $35 price target Investing.com
Pfizer's Oncology and Obesity Pipelines Support a Narrow Moat Despite Looming Patent Expirations ...
Pfizer's Oncology and Obesity Pipelines Support a Narrow Moat Despite Looming Patent Expirations Morningstar
Trump, Pfizer, and the art of a drug pricing deal - statnews.com
Trump, Pfizer, and the art of a drug pricing deal statnews.com
Pfizer's Global Health Fellows Program: Leveraging Colleagues’ Expertise to Help Improve Healthca...
Pfizer outlook, Humana leadership shake-up, Kraft Heinz's new CEO - Yahoo Finance
Pfizer outlook, Humana leadership shake-up, Kraft Heinz's new CEO Yahoo Finance
Science Drives Everything - Pfizer
Science Drives Everything Pfizer